Transform your recovery with integrative OUD care and chiropractic rehabilitation, focusing on holistic healing and support.

Educational Abstract: Integrative, Evidence-Based Strategies for Opioid Use Disorder in Special Populations, with Collaborative Medical Direction

In this educational post, I present a comprehensive, first-person exploration of the latest evidence-based strategies for treating opioid use disorder (OUD) across special populations—individuals with co-occurring mental health conditions, pregnant patients, adolescents, older adults, and those using central nervous system (CNS) depressants. I synthesize research findings from leading organizations and peer-reviewed studies and share clinical observations from my integrative chiropractic and functional medicine practice in El Paso, Texas. Under the medical direction of Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine) (NPI #1164426749, Texas MD License #J2933), our multidisciplinary team at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) integrates medical oversight, chiropractic care, functional medicine, rehabilitation, and personal injury care to optimize outcomes. I explain practical screening tools (PHQ-9, GAD-7, PCL-5), trauma-informed care principles, pharmacologic considerations (SSRIs/SNRIs; buprenorphine, methadone, naltrexone), risk management (QTc, serotonin syndrome), neonatal opioid withdrawal syndrome (NOWS) protocols, adolescent OUD approaches, and geriatric dosing nuances. I also demonstrate how integrative chiropractic care supports pain modulation, autonomic balance, mobility restoration, and adherence to MOUD, framed through clinical case vignettes and step-by-step rationale. Citations are provided in APA-7 format with hyperlinked references.

About Our Multidisciplinary Clinic and Leadership

• I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My clinical work focuses on integrative chiropractic care, functional medicine, pain recovery, and personal injury medicine. My clinical observations are shared on my sciatica resource site and professional profile:

• • https://sciatica.clinic/
  • https://www.linkedin.com/in/dralexjimenez/

• Our Medical Director and Collaborative Physician is Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933), with over 40 years of experience as an internist. Dr. Cardenas provides medical direction, diagnostic oversight, and pharmacologic management for complex cases, including OUD and comorbid medical conditions.
• Our clinic: Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic in El Paso, Texas. This integrated model is common in injury and functional care clinics where an MD leads medical direction while a chiropractor executes biomechanical restoration and rehabilitative care.
• Team integration:

• • Cardenas oversees diagnostics, medication-assisted treatment for OUD, cardiometabolic risk management, and coordination with psychiatry and obstetrics when relevant.
  • I deliver integrative chiropractic care to address pain generators, functional biomechanics, autonomic regulation, and structured rehabilitation that improves adherence to MOUD and reduces relapse drivers like pain, insomnia, and dysautonomia.
  • Functional medicine services evaluate root-cause contributors—nutritional status, inflammation, endocrine-metabolic imbalances, gut-brain axis dysregulation—that often perpetuate pain and cravings.
  • Personal injury care adds context around trauma recovery, biomechanics, and medicolegal coordination when injuries precipitate opioid exposure.
  • Behavioral health partnerships provide evidence-based psychotherapies and peer support necessary for co-occurring conditions.

The Clinical Landscape: Special Populations and Opioid Use Disorder

Key Topic Overview

• Co-occurring mental health conditions with OUD: depression, anxiety, PTSD
• Trauma-informed care principles and screening tools
• Evidence-based therapies and pharmacology (SSRIs/SNRIs)
• Medication-assisted treatment (MOUD): buprenorphine, methadone, naltrexone
• Safety considerations: QTc prolongation, serotonin syndrome
• OUD in pregnancy: screening, NOWS/Eat-Sleep-Console, breastfeeding, MOUD
• Adolescents: screening, protective/risk factors, buprenorphine approval ≥16
• Older adults: dosing, renal/hepatic function, respiratory depression risk
• CNS depressants and OUD treatment: risk-benefit management
• Integrative chiropractic care’s role across these populations

Co-Occurring Mental Health Conditions with Opioid Use Disorder

Why Co-Occurring Disorders Matter

• Approximately 21.5 million adults in the United States live with a co-occurring mental health disorder and substance use disorder, and OUD overlaps strongly with major depressive disorder (MDD), generalized anxiety disorder (GAD), and PTSD. Many receive mental health treatment more often than SUD-specific treatment, leaving OUD undertreated. This mismatch increases overdose risk and hinders recovery (Substance Abuse and Mental Health Services Administration [SAMHSA], 2022).
• Clinical experience shows that untreated depression and anxiety amplify pain perception, reduce adherence to care, and potentiate cravings. Conversely, an integrated plan that concurrently stabilizes mood and pain reduces relapse risk.

Screening Tools: Practical, Actionable Steps

• PHQ-9 for depression, GAD-7 for anxiety, PCL-5 for PTSD:

• • PHQ-9 thresholds guide severity and treatment intensity.
  • GAD-7 identifies anxiety’s functional impact and helps track improvement.
  • PCL-5 aligns with DSM-5 PTSD criteria; a score in the low 30s often indicates clinical need.
  • Reassess after initiating therapy or medication to quantify change. A 10-point PCL-5 reduction suggests therapeutic efficacy.

• What I do in practice:

• • At intake, Dr. Cardenas’s team administers PHQ-9, GAD-7, and, when trauma is suspected, PCL-5. We repeat tools at defined intervals (4–6 weeks) and after key interventions (start of SSRI/SNRI, structured CBT).

Trauma-Informed Care: The Six Principles

• Safety
• Trustworthiness and transparency
• Peer support
• Collaboration and mutuality
• Empowerment, voice, and choice
• Cultural, historical, and gender considerations
• Why it matters:

• • Trauma-informed care improves engagement, reduces re-traumatization, and supports autonomy—crucial for patients with histories of intimate partner violence and adverse childhood experiences.

• How we apply it:

• • Predictability in scheduling, clear consent around procedures, shared decision-making for MOUD selection, and peer support referrals. We create physically and emotionally safe clinical encounters by explaining what we’re doing and why, every step of the way.

Evidence-Based Psychotherapies

• Cognitive Behavioral Therapy (CBT) for depression and anxiety: targets maladaptive thoughts and behaviors that drive dysphoria and avoidance.
• For PTSD:

• • Prolonged Exposure (PE) helps extinguish conditioned fear.
  • Cognitive Processing Therapy (CPT) reframes trauma-related beliefs.
  • Eye Movement Desensitization and Reprocessing (EMDR) engages memory reconsolidation.

• Why these work physiologically:

• • CBT and trauma-focused modalities recalibrate the prefrontal cortex-limbic circuitry, reduce amygdala hyperreactivity, and improve emotion regulation, which lowers craving risk mediated by stress.

Pharmacologic Treatment for MDD, GAD, and PTSD with OUD

• SSRIs/SNRIs are first-line:

• • Paroxetine: broad indications but higher sexual dysfunction risk.
  • Sertraline: effective for MDD and PTSD; GI side effects may occur early.
  • Fluoxetine: long half-life aids adherence but may pose overdose concerns regarding suicidality.
  • Escitalopram: effective for MDD/GAD; may cause weight gain.
  • Duloxetine: lower sexual dysfunction risk; GI side effects; added benefit for neuropathic pain.
  • Venlafaxine: effective for MDD/GAD; watch for weight gain and QTc considerations.

• Rationale in OUD:

• • Treating mood and anxiety improves retention in MOUD programs and reduces self-medication with opioids.

Integrating SSRIs/SNRIs with MOUD: Risk-Benefit Nuances

• Buprenorphine:

• • Partial mu-opioid agonist with ceiling effect for respiratory depression; low risk of serotonin syndrome when combined with SSRIs/SNRIs.
  • Benefits often outweigh the theoretical risk; combining MOUD with antidepressant therapy increases treatment retention.

• Methadone:
  • Full agonist; monitor QTc prolongation, especially with citalopram or agents that increase QTc.
  • Cardiac safety plan:

• • • Baseline ECG
    • Repeat ECG after 5 half-lives of the added QTc-active drug
    • Annual ECG and symptom-triggered checks (palpitations, syncope, chest pain)

• Naltrexone:

• • Watch for mood changes; discuss black-box warnings on antidepressants for suicidality.
  • Shared decision-making emphasizes risk-benefit given the overdose risk of untreated OUD.

Serotonin Syndrome: Recognize and Respond

• SHIVERS acronym:

• • Shivering
  • Hyperreflexia and myoclonus
  • Increased temperature
  • Vital sign abnormalities (tachycardia, hypertension)
  • Encephalopathy
  • Restlessness
  • Sweating

• Action plan:

• • Immediate evaluation, medication review, supportive care; in severe cases, cyproheptadine is considered.

Case Vignette: Co-Occurring Depression/Anxiety with OUD

• Patient: 32-year-old mother, chronic low back pain due to degenerative disc disease, history of opioid misuse, maintained on buprenorphine-naloxone 8 mg TID, severe OUD, persistent depressive and anxiety symptoms.
• Screening:

• • PHQ-9: 18 (moderately severe)
  • GAD-7: 15 (severe)
  • PCL-5: 10 (no PTSD indication)

• Plan:

• • Continue buprenorphine-naloxone.
  • Initiate SSRI/SNRI; consider sertraline or duloxetine (dual benefit for pain and mood).
  • Refer to CBT; prescribe naloxone; discuss crisis options such as the 988 hotline.

• Integrative chiropractic care:

• • Pain modulation via lumbar stabilization, soft tissue release, graded exposure exercises, and autonomic regulation strategies (breathing training) reduces pain catastrophizing and improves function.
  • Functional medicine assessment: anti-inflammatory nutrition, sleep hygiene, and micronutrient optimization to reduce allostatic load.

Opioid Use Disorder in Pregnancy: Evidence-Based, Compassionate Care

Epidemiology and the Human Cost

• OUD prevalence in pregnancy increased significantly between 1999–2014 and again between 2010–2017. Neonatal opioid withdrawal syndrome (NOWS) rose in parallel, with infants born with NOWS every approximately 24 minutes in 2021. Rural regions often face higher rates due to access barriers.

Confronting Stigma

• Pregnant patients with OUD frequently report stigmatizing experiences—being labeled as unfit, drug-seeking, or criminal—which erodes trust and deters care. Trauma-informed, nonjudgmental engagement is essential for maternal and fetal safety.

Universal Screening in Pregnancy

• Tools:

• • Four Ps (Parents, Partners, Past, Present) for quick risk recognition.
  • NIDA Quick Screen for substance use within the past year; triggers specific follow-ups.
  • CRAFFT in younger pregnant individuals (<27 years), examining behavior risks.

• Protocol:

• • Universal application prevents bias and misses. Positive screens prompt confirmatory assessments and coordinated care with obstetrics.

Pregnancy Complications from OUD

• Elevated risks:

• • Placental abruption
  • Fetal growth restriction
  • Preterm birth
  • Stillbirth
  • Overdose

• Mechanisms:

• • Cycles of use and withdrawal induce hemodynamic swings and stress hormone surges (cortisol, catecholamines), compromising uteroplacental perfusion. Inconsistent prenatal care exacerbates risks.

Neonatal Opioid Withdrawal Syndrome (NOWS)

• Clarification:

• • DSM-5: Substance use disorder requires behavioral patterns; newborns experience withdrawal but are not “addicted.”

• Signs:

• • Tremors, feeding difficulties, high-pitched cry, diarrhea, vomiting, sleep problems, autonomic instability.

• Assessment:

• • Eat-Sleep-Console (ESC): simple, functional criteria—eat ≥1 ounce per feed, sleep ≥1 hour, console within 10 minutes.
  • Finnegan Scoring: detailed 21-item tool; many institutions prefer ESC for practicality and caregiver involvement.

• Outcomes:

• • NOWS duration: days to weeks depending on exposure.
  • No known lasting physical or intellectual problems when care is appropriate.
  • Rooming-in with mother encouraged; nonpharmacologic care (swaddling, skin-to-skin, breastfeeding) is foundational.

Pharmacologic Support for Newborns

• First-line: Morphine for significant NOWS; avoid naloxone in infants.
• Adjuncts: Clonidine, phenobarbital when indicated.

Breastfeeding Considerations

• Benefits:

• • Reduced infant illness (asthma, ear infections, eczema), lower SIDS risk, maternal benefits (lower cancer risks, reduced postpartum depression).

• Contraindications:

• • Return to non-prescribed opioid use, HIV, or certain incompatible medications.

• Safe with MOUD:

• • Breastfeeding is compatible with buprenorphine and methadone when managed properly.

MOUD in Pregnancy: Buprenorphine and Methadone

• Evidence:

• • Both are first-line, FDA-approved, and recommended by ACOG, SAMHSA, and WHO for improving maternal and neonatal outcomes.

• Naltrexone:

• • Not first-line; consider carefully with a risk-benefit discussion.

• Medically assisted withdrawal:

• • Not recommended due to high relapse and overdose risk.

• Neonatal outcomes:

• • Increased likelihood of normal birth weight and full-term delivery with MOUD; no evidence of congenital disabilities due to buprenorphine/methadone; observe infants for 3–4 days given maternal medication half-lives.

Case Vignette: Pregnancy and OUD

• Patient: 28-year-old, G2P1, 18 weeks pregnant, daily misuse of oxycodone ER (≈60 mg).
• Labs:

• • UDS positive for opioids; CBC, CMP, HIV, hepatitis, STI panel normal.

• Plan:

• • Initiate buprenorphine within 24 hours of last oxycodone dose; titrate from 2 mg to 24 mg as tolerated.
  • Prescribe naloxone; refer to prenatal care; psychosocial support; encourage breastfeeding if no contraindications.

• Integrative chiropractic care in pregnancy:

• • Pelvic alignment, sacroiliac stabilization, and gentle myofascial release reduce pregnancy-related low back pain, improve gait mechanics, and reduce sympathetic overdrive. This supports adherence to MOUD and prenatal visits.

• Functional medicine supports:

• • Nutritional counseling to reduce inflammation and stabilize glycemia, magnesium for muscle relaxation, sleep support, and stress coping strategies.

Adolescents with Opioid Use Disorder: Prevention, Early Intervention, and MOUD

Trends and Risks

• Overdose deaths in 14–18-year-olds surged, driven by high-potency illicitly manufactured fentanyl (IMFs), even as some self-reported usage patterns decreased. Most fatalities involve polysubstance scenarios.
• Many adolescents with OUD have psychiatric histories or prior opioid exposure; very few have received formal OUD treatment, highlighting a care gap.

Protective and Risk Factors

• Protective:

• • Family engagement, guardian disapproval of substance use, school connectedness, self-efficacy.

• Risk:

• • Social determinants of health, polysubstance use, early initiation, impulsivity, psychiatric disorders, maltreatment, familial SUD.

• Strategy:

• • Build buffers by involving family and schools, strengthening self-efficacy through skill-building and positive peer networks.

Confidentiality and Trust

• Explain confidentiality rules clearly at intake and maintain transparency about mandatory reporting. Establish one-on-one time to educate and deliver harm reduction advice.

Adolescent Screening Tools

• S2BI: frequency-based screening for tobacco, alcohol, and drugs over the past year.
• BSTAD: detailed days-used assessment and specific substance categories.
• CRAFFT: behavior-focused identification of risk patterns relevant to SUD.

Treatment Recommendations

• Naloxone:

• • Provide to adolescents, peers, and families; train on recognition and response. Encourage carrying naloxone in high-risk settings.

• Behavioral health:

• • School-based therapy, community services, and peer support groups.

• MOUD:

• • Buprenorphine is approved for ages 16+.
  • Methadone and naltrexone are generally approved at 18+.
  • Monitor emerging ASAM adolescent guidance anticipated in 2026.

Case Vignette: Adolescent Heroin Use

• Patient: 16-year-old, declined grades and attendance; postoperative oxycodone exposure led to heroin via peers; daily intranasal use; found drowsy and nauseated.
• UDS:

• • Positive for heroin; negative for fentanyl and other substances (important to discuss adulteration risks and harm reduction strategies).

• Plan:

• • Start buprenorphine 12–24 hours after last heroin use; titrate 2–24 mg as tolerated.
  • Prescribe naloxone; coordinate psychosocial support; school engagement plan.

• Integrative chiropractic care:

• • Lower extremity kinetic chain rehabilitation following ankle surgery to reduce residual pain and prevent relapse triggers.
  • Graded return to sport, balance training, and proprioceptive restoration to rebuild identity and resilience.

• Functional medicine:

• • Nutrition for neuroplasticity and recovery, sleep optimization, and guidance to reduce inflammation and improve cognitive performance.

Enhancing Health Together: Embracing Multidisciplinary Evaluation and Treatment- Video

Older Adults with Opioid Use Disorder: Safety, Dosing, and Monitoring

Rising Prevalence and Disparities

• OUD increased in adults aged 65–69 since 2013, with higher rates among those on Medicare/Medicaid. Disparities persist among Black Americans, Native Americans, and Alaska Natives.

Pharmacologic Considerations

• Risk-benefit framing:

• • Given the potency of fentanyl in the illicit supply, MOUD benefits often outweigh risks.

• Methadone:

• • Evaluate renal function; consider dose reduction if creatinine clearance is extremely low.
  • Monitor QTc; consider dose adjustments for QTc >450 ms in men and >460 ms in women.
  • Respiratory depression risk is higher due to full agonism and age-related pharmacokinetics.

• Buprenorphine:

• • Generally safer for respiratory depression; dose adjustments for severe hepatic impairment.
  • Avoid certain subcutaneous formulations in moderate-to-severe liver impairment.

• Strategy:

• • Close monitoring, conservative titration, regular ECGs, and interdisciplinary oversight.

Integrative chiropractic care for older adults

• Gentle mobilization, core stabilization, and balance training help reduce pain, improve mobility, and lower fall risk—supporting adherence to MOUD and reducing the need for analgesic escalation.
• Functional medicine:

• Assess sarcopenia, vitamin D status, omega-3 intake, and sleep architecture to improve pain thresholds and cognition.

CNS Depressants with MOUD: Managing Real-World Complexity

FDA Guidance and Clinical Judgment

• The FDA has urged caution against withholding MOUD in patients using benzodiazepines or other CNS depressants. The overdose risk from untreated OUD generally exceeds the additive respiratory depression risk of combined therapies.

Practical Steps

• Education:

• • Explain risks clearly; emphasize avoiding illicit opioids and alcohol while on MOUD.

• No arbitrary MOUD dose caps:

• • Do not reduce buprenorphine solely because of benzodiazepine co-use; titrate based on OUD control and withdrawal suppression.

• Tapering strategies:

• • If possible, gradually taper benzodiazepines, replacing with SSRIs/SNRIs and CBT for anxiety to reduce respiratory risk.

• Other CNS depressants:

• • Sedative-hypnotics, muscle relaxants (e.g., baclofen), antipsychotics (aripiprazole, paliperidone, quetiapine) require medication reconciliation and individualized risk-benefit analysis.

Autonomic Regulation through Integrative Care

• Chiropractic can aid autonomic balance by reducing nociceptive input and improving mechanoreceptive signaling from the spine and extremities. Combined with breathwork and paced exhalation, patients often report improved sleep and reduced anxiety—crucial when tapering CNS depressants.

How Integrative Chiropractic Care Fits into Opioid Use Disorder Treatment

Mechanisms: Why It Works

• Pain modulation:

• • By correcting segmental dysfunctions, reducing trigger points, and optimizing fascial glide, we reduce nociceptive load on the CNS. Less pain reduces the drive to self-medicate and supports stimulant-free functioning.

• Autonomic balance:

• • Spinal and rib cage mechanics influence respiratory patterns and vagal tone. Improved thoracic mobility facilitates diaphragmatic breathing, lowering sympathetic arousal that fuels cravings and anxiety.

• Biomechanical restoration:

• • Restoring kinetic chain integrity—lumbar-pelvic alignment, hip mobility, foot mechanics—decreases compensatory stress, enabling activity resumption that enhances dopamine reward in healthy ways.

• Sleep improvement:

• • Reducing neck and back pain decreases night-time arousals; better sleep normalizes pain thresholds and executive function, strengthening treatment adherence.

• Functional gains:

• • Graded activity and neuromuscular reeducation reinforce self-efficacy and help patients transition from passive care to active recovery.

Integrated Protocol: Step-by-Step

• Intake and triage:

• • Cardenas reviews medical risks, labs, and ECG if indicated. I perform a biomechanical and pain mapping assessment.

• MOUD initiation/optimization:

• • Buprenorphine or methadone selection via shared decision-making; naltrexone when appropriate.

• Mental health:

• • CBT/PE/CPT/EMDR referrals; SSRIs/SNRIs guided by comorbidities and side-effect profiles.

• Chiropractic plan:

• • Stabilization phases, soft tissue mobilization, joint adjustments when indicated, neurodynamic exercises, and breath training.

• Functional medicine layers:

• • Anti-inflammatory nutrition, micronutrient repletion, sleep timing, circadian hygiene, stress resilience training.

• Monitoring:

• • Reassess PHQ-9, GAD-7, PCL-5; pain scales; functional scores; MOUD adherence; side effects; ECGs where necessary.

• Peer support and relapse prevention:

• • Recovery groups, naloxone distribution, overdose education, and trigger planning.

Clinical Observations from Practice

• Patients who engage in structured rehabilitation alongside MOUD demonstrate:

• • Reduced pain catastrophizing and lower opioid craving intensity.
  • Improved sleep onset and maintenance after thoracic and cervical mobility work.
  • Higher adherence to MOUD and psychotherapies when physical function improves.

• Our sciatica-focused protocols:

• • Emphasize hip hinge mechanics, core bracing, and neurodynamic glides to decompress nerve roots and reduce peripheral sensitization.

• Outcomes:

• • Function gains frequently precede mood improvements, creating a positive feedback loop that stabilizes recovery trajectories.

Practical Algorithms and Safety Nets

When Initiating MOUD with SSRIs/SNRIs

• Baseline assessment:

• • PHQ-9/GAD-7/PCL-5; substance use screen; ECG if methadone is considered; labs (CBC, CMP, liver function).

• Start low, go slow:

• • Titrate antidepressants conservatively; monitor GI side effects and sexual dysfunction; consider duloxetine with neuropathic pain.

• Methadone-specific:

• • Avoid high-dose citalopram; consider alternatives with lower QTc impact; schedule ECG follow-ups.

• Buprenorphine:

• • Educate regarding precipitated withdrawal timing; consider microdosing protocols when transitioning from full agonists.

• Naltrexone:

• • Verify adequate opioid-free interval to prevent precipitation; discuss mood risks.

Pregnancy Pathway

• Universal screening; immediate obstetric collaboration.
• Initiate MOUD; avoid medically assisted withdrawal.
• Non-pharmacologic perinatal support; prepare for ESC-based newborn assessment.
• Encourage breastfeeding when compatible; rooming-in preferred.

Adolescents

• Establish confidentiality; leverage school networks.
• MOUD with buprenorphine if ≥16; naloxone training; family-engaged relapse prevention.
• Integrative rehab to rebuild athletic identity and social ties.

Older Adults

• Renal/hepatic evaluation; ECG monitoring; conservative dosing; fall risk prevention.
• Integrative care that emphasizes gentle mobilization, balance, and endurance.

CNS Depressants

• Do not withhold MOUD; taper benzodiazepines when feasible.
• Educate about overdose potential; maintain naloxone access; monitor sedation.

Synthesis and Clinical Takeaways

• Treat co-occurring psychiatric disorders in OUD—this increases MOUD retention and reduces relapse.
• MOUD during pregnancy is protective for mother and baby; neonatal outcomes are improved; breastfeeding is usually compatible with buprenorphine and methadone.
• Adolescents require early, trust-centered intervention, with buprenorphine available at age 16 and strong family-school collaboration.
• Older adults benefit from careful dose titration and monitoring, with buprenorphine often favored for respiratory safety.
• Benzodiazepines and other CNS depressants do not contraindicate MOUD; risk-benefit analysis and tapering strategies are key.
• Integrative chiropractic care addresses pain and autonomic dysregulation, improving functional capacity, sleep, and adherence to MOUD—crucial pillars across all special populations.
• Our MD-chiropractic functional medicine model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso ensures medical safety, whole-person care, and rehabilitative progression guided by evidence-based protocols.

References

• Substance Abuse and Mental Health Services Administration. (2022). 2022 National Survey on Drug Use and Health (NSDUH).
• American College of Obstetricians and Gynecologists. (2017). Opioid Use and Opioid Use Disorder in Pregnancy. Committee Opinion No. 711.
• World Health Organization. (2014). Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence.
• S. Food and Drug Administration. (2017). FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants.
• Centers for Disease Control and Prevention. (2022). Trends in Drug Overdose Deaths among Adolescents.
• Department of Health and Human Services. (2023). Eat, Sleep, Console: A Family-Centered Approach to Neonatal Opioid Withdrawal Syndrome.
• American Society of Addiction Medicine. (2020). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.

SEO tags: opioid use disorder, co-occurring mental health, pregnancy and OUD, neonatal opioid withdrawal syndrome, Eat Sleep Console, SSRIs, SNRIs, buprenorphine, methadone, naltrexone, QTc prolongation, serotonin syndrome, adolescents OUD, older adults OUD, benzodiazepines CNS depressants, functional medicine, integrative chiropractic, rehabilitation, El Paso Injury Medical Clinic, Dr. Maria Guadalupe Cardenas MD, Dr. Alex Jimenez DC